Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-Current Assets (2016 - 2025)

Protalix BioTherapeutics has reported Non-Current Assets over the past 16 years, most recently at $15.7 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $15.7 million for Q4 2025, up 17.5% from a year ago — trailing twelve months through Dec 2025 was $57.8 million (up 3.9% YoY), and the annual figure for FY2025 was $15.7 million, up 17.5%.
  • Non-Current Assets for Q4 2025 was $15.7 million at Protalix BioTherapeutics, down from $15.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for PLX hit a ceiling of $15.8 million in Q3 2025 and a floor of $10.9 million in Q4 2022.
  • Median Non-Current Assets over the past 5 years was $13.2 million (2024), compared with a mean of $13.1 million.
  • Biggest five-year swings in Non-Current Assets: plummeted 51.83% in 2021 and later skyrocketed 36.55% in 2023.
  • Protalix BioTherapeutics' Non-Current Assets stood at $12.0 million in 2021, then decreased by 9.1% to $10.9 million in 2022, then surged by 32.96% to $14.5 million in 2023, then fell by 8.02% to $13.3 million in 2024, then increased by 17.5% to $15.7 million in 2025.
  • The last three reported values for Non-Current Assets were $15.7 million (Q4 2025), $15.8 million (Q3 2025), and $13.0 million (Q2 2025) per Business Quant data.